Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AR | P10275 | 2/20 | 0.40 |
| ▸ | PGR | P06401 | 2/20 | 0.36 |
| ▸ | CYP11B2 | P19099 | 5/20 | 0.36 |
| ▸ | CYP11B1 | P15538 | 4/20 | 0.36 |
| ▸ | ABL1 | P00519 | 2/20 | 0.34 |
| ▸ | KDM1A | O60341 | 1/20 | 0.33 |
| ▸ | MAPK14 | Q16539 | 2/20 | 0.33 |
| ▸ | STS | P08842 | 1/20 | 0.33 |
| ▸ | ESR1 | P03372 | 1/20 | 0.33 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.33 |
| ▸ | GRM5 | P41594 | 1/20 | 0.32 |
| ▸ | EGLN2 | Q96KS0 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16122301 | 0.89 | NSD2 (0.36) | ARPGRCYP11B2CYP11B1ABL1 | |
| SCHEMBL16122715 | 0.81 | GRM5 (0.39) | ARCYP11B2CYP11B1GRM5 | |
| SCHEMBL16122302 | 0.78 | MAP4K4 (0.38) | ARPGRCYP11B2CYP11B1GRM5 | |
| SCHEMBL19532032 | 0.77 | AR (0.35) | ARPGRCYP11B2CYP11B1 | |
| SCHEMBL16122530 | 0.76 | CYP11B1 (0.46) | CYP11B2CYP11B1GRM5 | |
| SCHEMBL17545813 | 0.75 | TRPV4 (0.35) | CYP11B2CYP11B1STSGRM5 | |
| SCHEMBL16122334 | 0.75 | KIF11 (0.53) | ARCYP11B2CYP11B1STS | |
| SCHEMBL16122710 | 0.75 | CYP11B2 (0.41) | ARPGRCYP11B2CYP11B1ESR1 | |
| SCHEMBL16122528 | 0.75 | CYP11B1 (0.44) | CYP11B2CYP11B1GRM5 | |
| SCHEMBL16122531 | 0.74 | METAP2 (0.45) | ARCYP11B2CYP11B1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2976322-B1 | SYNTHETIC BUILDING BLOCKS FOR THE PRODUCTION OF MATERIALS FOR ORGANIC ELECTROLUMINESCENCE DEVICES | MERCK PATENT GMBH (DE) | 2019-11-20 | — | — | EP | disclosed |
| US-10407384-B2 | Synthetic building blocks for the production of materials for organic electroluminescence devices | MERCK PATENT GMBH (DE) | 2019-09-10 | — | — | US | disclosed |
| US-20170313650-A1 | SYNTHETIC BUILDING BLOCKS FOR THE PRODUCTION OF MATERIALS FOR ORGANIC ELECTROLUMINESCENCE DEVICES | UDC IRELAND LIMITED (IE) | 2017-11-02 | — | — | US | disclosed |
| US-9718764-B2 | Synthetic building blocks for the production of materials for organic electroluminescence devices | MERCK PATENT GMBH (DE) | 2017-08-01 | — | — | US | disclosed |
| US-20160046563-A1 | SYNTHETIC BUILDING BLOCKS FOR THE PRODUCTION OF MATERIALS FOR ORGANIC ELECTROLUMINESCENCE DEVICES | UDC IRELAND LIMITED (IE) | 2016-02-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160046563-A1 | SYNTHETIC BUILDING BLOCKS FOR THE PRODUCTION OF MATERIALS FOR ORGANIC ELECTROLUMINESCENCE DEVICES | TBCB, CYBA, BMP2 | AR 4588/4885PGR 4217/4885CYP11B2 1484/4885 |
| US-10407384-B2 | Synthetic building blocks for the production of materials for organic electroluminescence devices | TBCB, CYBA, BMP2 | AR 4588/4885PGR 4217/4885CYP11B2 1484/4885 |
| US-20170313650-A1 | SYNTHETIC BUILDING BLOCKS FOR THE PRODUCTION OF MATERIALS FOR ORGANIC ELECTROLUMINESCENCE DEVICES | TBCB, CYBA, BMP2 | AR 4588/4885PGR 4217/4885CYP11B2 1484/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.